Worldwide Prescription Drug Sales to Top Trillion Dollar Mark in 2022 with 32% of the 2022 Increase in Sales to Come From Orphan Drugs

LONDON, BOSTON, SAN FRANCISCO, TOKYO (June 13, 2017) — Life science commercial intelligence firm, Evaluate, is launching their annual complimentary industry report, “EvaluatePharma World Preview 2017, Outlook to 2022” at the annual BIO International Convention in San Diego, June 19-22, 2017, Booth #3627.

The report, which sets the industry standard for consensus forecasts for the life sciences, provides an overview of the sector including key trends, patent expiry impact, top products and companies, R&D spend and consensus forecasts to 2022. Complimentary copies of the executive summary will be available in the Evaluate Booth #3627. Follow @evaluatepharma on Twitter to receive download link for the full report on release date June 20th or visit

The Evaluate team will also showcase key new data sets and analyses designed to support faster and more accurate asset screening, appraisal and forecasting for their clients high value decisions, including:

  • Regional sales forecast coverage expanded for US, Europe and Japan
  • R&D Analyzer – transparent benchmark and drug-specific Probability of Technical and Regulatory Success (PTRS), predictive timeline and R&D cost metrics alongside clinical trial endpoints and outcomes in a single view
  • Epi Analyzer – Epidemiology and patient segmentation analysis for 8,000 sub-populations across 160 indications

In attendance to discuss the report findings and latest analyses will be Anthony Raeside, Head of Research; Antonio Iervolino, Head of Forecasting; Andy Williams, Head of Product Management and Paul Verdin, PhD Head of Custom Services. Staff from the UK, Japan and US offices will also be in attendance. Meetings can be scheduled by going to or through the BIO Partnering system, or simply stop by the Evaluate Booth #3627 where there is a private meeting space.

About Evaluate Ltd

Since 1996, Evaluate, a Norstella company, has provided the life sciences industry with the data, insight and intelligence to facilitate confident decision making on high-value investments in treatments and markets. We enable our clients to embed our proprietary and industry data into their workflows, tools and processes so they can work more effectively and efficiently. For more information about Evaluate, visit and follow us on LinkedIn and Twitter.

About Norstella

Norstella consists of several prominent pharmaceutical solutions providers—Citeline, Evaluate, MMIT, Panalgo, and The Dedham Group. United by a shared mission, to help patients gain access to life-saving therapies. Norstella offers comprehensive insights throughout the drug development lifecycle, leveraging unparalleled data, cutting-edge technology, and expert insights and consultancy. For more information, visit Norstella and follow on LinkedIn.